×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
LS50: Transformation and Innovation in Drug Development with Environmental Changes Induced by COVID-19
Session Chair(s)
Marie Shiga
Manager, Health Industries Advisory
PwC Consulting LLC, Japan
- Introduction of the session - Transformation and innovation in drug development with environmental changes induced by COVID-19
Speaker(s)
Michiyo Ohshima, MBA
Pfizer R&D GK, Japan
Senior Director, Head of Japan Portfolio and Project Management
Noboru Yamamoto, MD, PhD
National Cancer Center Hospital, Japan
Deputy Director, Department of Experimental Therapeutics
Minori Niso
Parexel, Japan
Brand Marketing Director, APAC Marketing
Have an account?